Investing Club’s Q2 2023 Earnings Report Card
The third quarter was a turning point, yanking us out of an earnings recession that put up three straight quarters of negative growth. Supply chains loosened up, allowing more orders …
Eli Lilly and Co
Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be …
Wall Street analysts name 13 of our stocks as top picks for 2024
This year’s powerful rally has more than made up for the carnage of 2022 on Wall Street. Tech stocks reasserted their leadership and even some out-of-favor sectors perked up in …
5 things to know before the stock market opens Monday
Here are the most important news items that investors need to start their trading day: 1. Roaring to a record Stocks are on a tear heading into the last full …
2024 expectations for Wegovy, Ozempic, Zepbound
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed …
New data on Eli Lilly’s weight-loss drug shows its outlook is bright
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said …
Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to …
Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain …
Pfizer to discontinue twice-daily version of weight loss pill
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the …
A handful of stocks led the market in 2023. Here’s why we still own 35
The stock market this year has been led by just a handful of the biggest and best tech companies. It’s enough to make you question the whole idea of diversification. …